Bryan Hubbard and the Kentucky Attempt

Bryan Hubbard made the first serious attempt to put American public money behind ibogaine, and it did not work. Understanding why is more useful than any of the announcements that followed it.

Who he is

A lawyer by background, with sixteen years in workers’ compensation practice before moving into Kentucky state government. He served as commissioner of the state’s Department for Income Support and in the Attorney General’s Medicaid fraud office, then chaired the Kentucky Opioid Abatement Advisory Commission.

That last post is the one that matters. The commission controlled the state’s half of Kentucky’s opioid settlement money, the other half going directly to cities and counties, and Hubbard proposed committing part of it to research intended to bring ibogaine to FDA approval.

What happened in Kentucky

The proposal was the first of its kind: settlement funds, paid by companies held responsible for the opioid epidemic, directed at an unapproved Schedule I drug as a treatment for opioid dependence.

It did not survive a change of attorney general. Hubbard proposed forty-two million dollars in 2023 under Attorney General Daniel Cameron. Cameron’s successor, Russell Coleman, asked Hubbard to resign in December 2023, and in March 2024 asked the commission to step back from the proposal, describing the trial as unproven and expensive. The money was never committed.

The order matters. The proposal did not lose an argument on its merits before the body that controlled the money: the chair who authored it was replaced after an election, and his successor withdrew it.

Kentucky did later enact an ibogaine framework, over a governor’s veto in April 2026, but its proposed money had already been removed in committee weeks earlier. The state has a mechanism and no appropriation, as set out on ibogaine and Kentucky law.

What he does now

In June 2025 he became the first chief executive of Americans for Ibogaine, the advocacy organisation chaired by Rick Perry. He had previously directed the American Ibogaine Initiative, supported by a private foundation.

So the campaign that began inside a state commission now runs from a national non-profit, and the same person leads it. That trajectory, from public body to advocacy organisation, is worth knowing when reading claims about state enthusiasm for ibogaine. The same organisation campaigns in several of the states involved, and says so publicly.

What he claims, and what is established

Hubbard argues publicly that ibogaine interrupts addiction and restores neurotransmitter function. At the 2026 SXSW panel he put it more strongly than we have just done, describing a unique capacity to restore dopamine and serotonin production in the opioid-impaired brain to pre-use levels, regardless of how much or how long a person had used.

The first half is the subject of active research and no completed Phase 3 trial. The second is a mechanistic claim that outruns what human evidence supports. What this site can establish about the risks any such programme has to answer for is on ibogaine and the heart, and what the published adverse-event record contains is on ibogaine side effects.

Reporting what an advocate says is not endorsing it, and on a subject where the advocacy is this concentrated, the distinction is the whole job.